Autosomal semi-dominant severe lipodystrophic laminopathy

Autosomal semi-dominant severe lipodystrophic laminopathy is an extremely rare genetic disorder caused by mutations in the LMNA gene, which encodes lamin A/C, a structural protein of the nuclear envelope. This condition belongs to the broader group of laminopathies — diseases caused by defects in nuclear lamin proteins. The term 'semi-dominant' reflects that heterozygous carriers may show a milder phenotype, while homozygous or compound heterozygous individuals manifest a more severe clinical presentation. The disease is characterized by severe generalized or partial lipodystrophy (loss of subcutaneous adipose tissue), which leads to significant metabolic complications including severe insulin resistance, diabetes mellitus, hypertriglyceridemia, and hepatic steatosis (fatty liver). Patients may also develop features overlapping with other laminopathies, such as progeroid (premature aging) features, cardiomyopathy, and muscular involvement. The loss of fat tissue disrupts normal metabolic regulation, placing patients at high risk for cardiovascular disease and pancreatitis secondary to elevated triglycerides. Treatment is primarily supportive and focused on managing metabolic complications. This includes dietary management with a low-fat diet, insulin-sensitizing agents, lipid-lowering medications, and in some cases metreleptin (recombinant leptin) therapy to address leptin deficiency resulting from fat loss. Cardiac monitoring is recommended given the risk of cardiomyopathy. There is currently no curative therapy, and management requires a multidisciplinary approach involving endocrinology, cardiology, and genetics specialists.

Common questions about Autosomal semi-dominant severe lipodystrophic laminopathy